Rechercher des projets européens

20 projets européens trouvés

Recherche sur 125080 projets européens

 TERMINÉ 

SIMVASTATIN AND RIFAXIMIN AS NEW THERAPY FOR PATIENTS WITH DECOMPENSATED CIRRHOSIS (LIVERHOPE)

Date du début: 1 janv. 2017, Date de fin: 31 déc. 2021,

Liver cirrhosis is a very common chronic disease and one of the leading causes of death in European. Moreover, cirrhosis has a marked impact in patients quality of life and represents a major burden for health systems. Treatment of cirrhosis is currently based on symptomatic management of complications and has not changed substantially in the last 20 years. There is an unmet need for therapies tha ...
Voir le projet

 18

 TERMINÉ 

A multicenter phase IIb study using HLA-unmatched allogeneic placenta-derived stromal cells (PLX-PAD) for the treatment of severe critical limb ischemia accompanied by mechanistic studies (PACE)

Date du début: 1 janv. 2017, Date de fin: 31 déc. 2020,

PACE aims to transform the treatment of patients suffering from critical limb ischemia (CLI), a disease with high medical need, because of limited treatment options and poor outcome by applying a novel, off-the-shelf allogeneic placenta-derived stromal cell product (PLX-PAD). Despite improvements in medical care and revascularization, patients with CLI continue to have a high risk of major amputat ...
Voir le projet

 9

 TERMINÉ 

Mechanisms underlying hepatocellular carcinoma pathogenesis and impact of co-morbidities. (HEP-CAR)

Date du début: 1 janv. 2016, Date de fin: 31 déc. 2019,

Hepatocellular carcinoma (HCC) is the most common liver malignancy, with an estimated 750,000 new cases and 695,000 deaths per year, rating third in incidence and mortality in the world. Whilst incidence and mortality for other cancers are declining, HCC represents an increasing public health problem in Europe with men having a higher incidence than women. Several liver diseases lead to HCC and be ...
Voir le projet

 9

 TERMINÉ 

An integrated approach to dissect determinants, risk factors and pathways of ageing of the immune system. (ImmunoAgeing)

Date du début: 1 mai 2015, Date de fin: 30 avr. 2019,

Age-related changes in the immune system, also known as ‘immunosenescence’, have a huge detrimental impact on the health of our ageing populations. However, the extent and mechanisms of the changes, and thus possible routes to prevention or alleviation, are largely unknown. We propose to analyse immunosenescence with unprecedented resolution by determining in large cohorts of volunteers the change ...
Voir le projet

 4

 TERMINÉ 

Biomarker Development for Postoperative Cognitive Impairment in the Elderly (BioCog)

Date du début: 1 févr. 2014, Date de fin: 31 janv. 2019,

Postoperative delirium (POD) is characterized by the progressive deterioration of sensory/cognitive function after surgery with incidences of up to 30-80%. It is frequently followed by postoperative cognitive dysfunction (POCD) which tends to persist over time. In elderly patients, POCD resembles chronic dementia and appears to accelerate the cognitive decline in Alzheimer dementia. POD is strongl ...
Voir le projet

 12

 TERMINÉ 

Human cystic Echinococcosis ReseArch in CentraL and Eastern Societies (HERACLES)

Date du début: 1 oct. 2013, Date de fin: 30 sept. 2018,

Human cystic echinococcosis (CE), one of the most widespread helminthic zoonoses, is a chronic disease caused by infection with the larval stage of the tapeworm Echinococcus granulosus. This disease is highly endemic in some southern (Spain and Italy), eastern (Bulgaria and Romania) European countries and associated (Turkey) countries, where it still represents a major health and economic problem. ...
Voir le projet

 10

 TERMINÉ 

Targeting and exploiting B cell functions for treatment in cardiovascular disease (Athero-B-Cell)

Date du début: 1 sept. 2013, Date de fin: 31 août 2018,

Cardiovascular disease (CVD) mortality and morbidity is predicted to increase in Europe and worldwide in the next decades due to aging and the rise of diabetes and obesity. The link between metabolic and inflammatory disease is getting stronger, raising hopes for novel therapeutic targets to be exploited clinically. Clinical evidence generated by the Academic partners of the Athero-B-Cell Consorti ...
Voir le projet

 11

 TERMINÉ 

Targeting novel lipid pathways for treatment of cardiovascular disease (Athero-Flux)

Date du début: 1 sept. 2013, Date de fin: 31 août 2018,

Lipid lowering has significantly reduced cardiovascular disease (CVD) mortality in EU. However, the aim to abolish CVD in EU is far from achieved and attempts to improve on the benefits of statins with new agents have not yet delivered new therapeutics. The Consortium Athero-Flux builds on FP7-generated large-scale lipidomics data showing that specific sphingolipids and in particular distinct cer ...
Voir le projet

 12

 TERMINÉ 

Pathogen COinfection: HIV, Tuberculosis, Malaria and Hepatitis C virus (PathCO)

Date du début: 1 nov. 2012, Date de fin: 31 oct. 2017,

Acquired immune deficiency (AIDS), tuberculosis (TB) and malaria are the primary infectious diseases causing death world wide. In addition to these pathogens, 170 million people are infected with hepatitis C virus (HCV), which leads to chronic liver disease. Because of shared routes of transmission, HCV co-infection is recognized as a major cause of morbidity and mortality among HIV-1 infected per ...
Voir le projet

 11

 TERMINÉ 

Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome and health-economic data of transplantation (BIO-DrIM)

Date du début: 1 nov. 2012, Date de fin: 31 oct. 2017,

Organ transplantation has emerged as the “gold standard” therapy for end-stage organ failure. Incomplete control of chronic allograft injury but also the adverse effects of long-term immunosuppression (IS) continue to challenge the long-term success of transplantation. The paradigm is shifting from increasing “net”-IS by novel drugs to the concept of minimizing long-term IS as early as possible. H ...
Voir le projet

 17

 TERMINÉ 

A Unified Approach to Evaluating Cellular Immunotherapy in Solid Organ Transplantation (THE ONE STUDY)

Date du début: 1 nov. 2010, Date de fin: 31 oct. 2017,

Preventing immunological rejection of transplanted organs without the need for long-term use of pharmacological immunosuppression is a primary objective in transplantation medicine. Reducing the need for immunosuppression would dramatically improve the outcome for transplant recipients and reduce health costs for society. The means to achieve this goal has not been realised with pharmacological or ...
Voir le projet

 16

 TERMINÉ 

Advanced Immunization Technologies (ADITEC)

Date du début: 1 oct. 2011, Date de fin: 30 sept. 2017,

Vaccines so far have been developed mostly by following an empiric approach. To prevent and possibly cure unresolved and emerging infectious diseases we need to fully exploit the potential of the human immune system. Progress in science and technology makes it possible to achieve what was previously deemed impossible. The scope of this project is to produce knowledge necessary to develop novel and ...
Voir le projet

 53

 TERMINÉ 

Anti-Biopharmaceutical Immunization:Prediction and analysis of clinical relevance to minimize the risk (ABIRISK)

Date du début: 1 mars 2012, Date de fin: 28 févr. 2017,

The ABIRISK project provides an integrated approach to the study of immunization against biopharmaceuticals, bringing together a unique panel of experts from different disciplines. ABIRISK will involve many of the European leaders in rheumatology, gastroenterology, hemophilia and multiple sclerosis, caring for ~30,000 patients treated with biopharmaceuticals, with ~10,000 additional patients recru ...
Voir le projet

 39

 TERMINÉ 

Integrating chemical approaches to treat pancreatic cancer: making new leads for a cure (Panacreas)

Date du début: 1 mars 2011, Date de fin: 29 févr. 2016,

Pancreatic ductal adenocarcinoma (PDAC) causes 34000 deaths in the EU every year. Conventional cancer treatments have close to no impact on this disease. As a result, almost all patients diagnosed with PDAC develop metastases and eventually die. Given this poor outlook, the search for new therapeutics is mandatory. These will have to target relevant cancer pathways and be designed based on the ava ...
Voir le projet

 12

 TERMINÉ 

Targeting Src-family tyrosine kinases in chronic autoimmune and inflammatory diseases (TARKINAID)

Date du début: 1 janv. 2012, Date de fin: 31 déc. 2015,

The project aims to develop novel inhibitors of chronic autoimmune and inflammatory diseases by targeting members of the Src tyrosine kinase family. Src-family kinases have recently emerged as major therapeutic targets in malignant diseases but their suitability as potential targets of inflammatory diseases has not yet recieved widespread acceptance. On the other hand, members of the applicant con ...
Voir le projet

 11

 TERMINÉ 

TargetIng novel MEchanisms of Resolution in inflammation (TIMER)

Date du début: 1 janv. 2012, Date de fin: 31 déc. 2015,

Resolution of inflammation is a key determinant of pathology, and an active process which involves diverse pathways and molecules. The general objective of the TIMER Consortium is to identify and validate new molecules involved in the resolution of inflammation as a basis for the development of innovative therapeutic strategies in chronic inflammatory and autoimmune diseases. The project will invo ...
Voir le projet

 13

 TERMINÉ 

"Fungi in the setting of inflammation, allergy and autoimmune diseases:Translating basic science into clinical practices" (ALLFUN)

Date du début: 1 déc. 2010, Date de fin: 31 mai 2014,

"The ALLFUN proposal aims at defining the cellular and molecular mechanisms by which ubiquitous airborne or commensal fungi contribute to immune homeostasis and its dysregulation leading to allergy and inflammatory diseases. Breakthroughs in understanding how mucosal homeostasis is established, maintained or disrupted in the presence of fungi should be sources of new therapeutic targets and drugs ...
Voir le projet

 14

 TERMINÉ 

Development of carbon monoxide releasing molecules for the treatment of rheumatoid arthritis (CORMRA)

Date du début: 1 nov. 2009, Date de fin: 31 oct. 2011,

"The project will focus on the pre-clinical development of carbon monoxide releasing molecules (CORMs) for the treatment of rheumatoid arthritis (RA). Carbon monoxide (CO) has been shown, by several renowned laboratories around the world, to have a number of anti-inflammatory properties which turn it into an exceptionally promising compound against chronic inflammatory diseases such as RA. In its ...
Voir le projet

 7

 TERMINÉ 

Set up and comparison of multiple stem cell approaches for kidney repair (STAR-T REK)

Date du début: 1 nov. 2008, Date de fin: 31 oct. 2011,

"With the increasing rate of end-stage renal failure and limited alternatives for its treatment, potential regenerative approaches for kidney damages are urgently needed. Because of the complexity of the organ, the development of stem cell therapies for kidney is still in its infancy. Identifying which cell types are capable of beneficial effects is the critical step required to realize the potent ...
Voir le projet

 11

 TERMINÉ 

Design of a vaccine to immunize neonates against GBS infections through a durable maternal immune response (DEVANI)

Date du début: 1 janv. 2008, Date de fin: 30 juin 2011,

"Direct vaccination cannot prevent diseases that affect neonates in the first days of life. Group B Streptococcus (GBS) is the major cause of neonatal septicemia and meningitis affecting up to one in every thousand live births. Over 80% of cases occur in the first 7 days after birth and the remaining 20% of disease occurs between 8-90 days after birth. Studies carried out in the USA indicate that ...
Voir le projet

 10